Cargando…
The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis
PURPOSE: Three dopamine agonists [bromocriptine, cabergoline, and quinagolide (CV)] have been used for hyperprolactinemia treatment for decades. Several studies have reviewed the efficacy and safety of bromocriptine and cabergoline. However, no systematic review or meta-analysis has discussed the ef...
Autores principales: | Zeng, Yanyang, Huang, Qingliang, Zou, Yunzhi, Tan, Jiacong, Zhou, Wu, Li, Meihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902948/ https://www.ncbi.nlm.nih.gov/pubmed/36761195 http://dx.doi.org/10.3389/fendo.2023.1027905 |
Ejemplares similares
-
Total Synthesis of (±)-Quinagolide: A Potent
D(2) Receptor Agonist for the Treatment of Hyperprolactinemia
por: Chavan, Subhash P., et al.
Publicado: (2019) -
The prevalence of thyroid dysfunction and hyperprolactinemia in women with PCOS
por: van der Ham, Kim, et al.
Publicado: (2023) -
Quinagolide Treatment Reduces Invasive and Angiogenic Properties of Endometrial Mesenchymal Stromal Cells
por: Iampietro, Corinne, et al.
Publicado: (2022) -
Diagnostic criteria of small sellar lesions with hyperprolactinemia: Prolactinoma or else
por: Cho, Anna, et al.
Publicado: (2022) -
SUN-043 Galactorrhea and Hyperprolactinemia in a Transgender Female
por: Unnithan, Rachna, et al.
Publicado: (2020)